Fenbendazole affects the p53 tumor suppressor pathway through several distinct molecular mechanisms:
1. Enhanced Sensitivity in Wild-Type p53 Cancer Cells
Selective Toxicity: Cancer cell lines expressing wild-type (WT) p53 (such as A549 and H460) display significantly greater sensitivity to fenbendazole-induced growth inhibition and apoptosis compared to p53-mutant or p53-null cell lines.
Restoration of Sensitivity: When p53-null cells (such as H1299) are transfected with a wild-type p53 expression construct, exposure to fenbendazole successfully restores apoptotic cell death.
2. Stabilization and Nuclear Accumulation
Fenbendazole treatment leads to a dose-dependent increase in the nuclear accumulation of WT p53.
This accumulation is associated with steady levels of acetylated tubulin, which supports the microtubule-dependent nuclear trafficking of active p53 protein.
3. Translocation to Mitochondria and Apoptosis
Beyond nuclear activity, fenbendazole promotes the translocation of p53 to the mitochondria.
Specifically, an increased pool of monoubiquitinated p53 translocates to the mitochondrial fraction.
This mitochondrial localization triggers mitochondrial membrane depolarization (measured by JC-1 dye), cytochrome c release, and intrinsic apoptotic cell death.
4. Transcriptional Activation of Metabolic & Pro-Apoptotic Genes
The p53 protein induced by fenbendazole is transcriptionally active and upregulates key p53 target genes involved in cell cycle regulation, apoptosis, and energy metabolism:
Cell Cycle & Feedback Control: Upregulates p21 and MDM2.
Metabolic & Apoptotic Targets: Induces TIGAR, SCO2, Glutaminase 2 (GLS2), Proline Oxidase, ALDH4A1, GPX1, and Sestrin.
5. Regulation of the Warburg Effect
Working in tandem with tubulin depolymerization, p53 activation following fenbendazole treatment leads to the downregulation of the GLUT-4 glucose transporter and Hexokinase II (HK II).
This shuts down glucose uptake and suppresses glycolysis in tumor cells.
6. In Vivo Activation in Tumors
In mouse xenograft models bearing A549 tumors, oral administration of fenbendazole resulted in a high density of p53-positive tumor cells accompanied by widespread intratumoral apoptosis.
Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 8, Article 11926. https://doi.org/10.1038/s41598-018-30158-6